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Abstract
Introduction: Vancomycin, a glycopeptide antibiotic, is used to treat resistant gram-positive
infections. There has been a 10- to 20-fold increase in its use over the past 25 years. Although
ototoxicity and nephrotoxicity are well known side effects of vancomycin, it can also induce platelet
reactive antibodies leading to life-threatening thrombocytopenia. Vancomycin is often clinically
overlooked as a cause of thrombocytopenia, especially in a scenario of sepsis or when there is use of
heparin. We report a proven case of vancomycin-induced thrombocytopenia and its reversal after
discontinuation of vancomycin.
Case presentation: A 60-year-old man with a history of hypertension, congestive heart failure and
dyslipidemia was admitted for a right shoulder rotator cuff tear. He underwent right-shoulder
arthroscopy and rotator cuff repair. About three weeks later, he developed pain, swelling and
purulent drainage from his right shoulder. Arthroscopic irrigation and drainage was then performed.
Intraoperative fluid revealed the presence of Methicillin susceptible Staphylococcus aureus, vancomycin-
sensitive Enterococcus spp. and Serratia marcescens. The patient had no known allergies. After
reviewing his antimicrobial susceptibility, he was started on vancomycin 1500 mgs intravenously
every 12 hours (to treat both Staphylococcus aureus and Enterococcus spp) and ciprofloxacin 750 mgs
by oral induction every 12 hours. The patient’s condition improved following antibiotic treatment. He
was discharged and allowed to go home on IV vancomycin and oral ciprofloxacin. The patient’s
platelet count on the day of starting vancomycin therapy was 253 × 10
3/mm
3. At weeks one, two and
three, the counts were 231 × 10
3/mm
3, 272 × 10
3/mm and 6 × 103/mm
3, respectively. The patient
was admitted for further work-up of the thrombocytopenia. He was later shown to have
vancomycin-induced platelet-reactive antibodies, causing significant thrombocytopenia, and then
reversal after his vancomycin medication was discontinued.
Conclusion: Thrombocytopenia is a potentially life-threatening condition. Vancomycin is often
clinically overlooked as a cause of thrombocytopenia, especially in a scenario of sepsis or when there
is use of heparin. Simple laboratory testing with drug-dependent antibodies can be helpful in
identifying vancomycin as a cause of thrombocytopenia.
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Vancomycin, a glycopeptide antibiotic, is used to treat
resistant gram-positive infections [1-5]. Recent studies
show a 10- to 20-fold increase in its use over the past
25 years [5-7]. Nephrotoxicity (associated with elevated
trough levels), ototoxicity associated with elevated peak
levels, red-man syndrome and reversible neutropenia are
well known side effects of vancomycin. Thrombocytope-
nia related to vancomycin is rarely reported in the
literature [1,8-11]. This may be due to co-morbid
conditions and/or concurrent medications. Furthermore,
vancomycin as a cause of thrombocytopenia may be
overlooked, especially in a scenario of sepsis or when
heparin is used [5,12-14]. Drygalski et al. [5] reported that
vancomycin can induce platelet-reactive antibodies, lead-
ing to thrombocytopenia and life-threatening bleeding
complications. We report a proven case of vancomycin-
induced platelet-reactive antibodies causing significant
thrombocytopenia, and then reversal after discontinuation
of vancomycin medication.
Case presentation
A 60-year-old man with a history of hypertension,
congestive heart failure, dyslipidemia and gastro-esopha-
geal reflux disease was admitted for right shoulder rotator
cuff tear. His medications included spironolactone 25 mg
once daily, aspirin 325 mg once daily, pantoprazole 40 mg
once daily, olmesartan 40 mg once daily, colesevelam
625mgthreetimesaday,furosemide20mgoncedailyand
ezetimibe 10 mg once daily. The patient then underwent
right shoulder arthroscopy and rotator cuff repair.
The postoperative course was uneventful until three weeks
later, when he developed pain, swelling and a purulent
drainage from his right shoulder. The patient returned to
the emergency department and an arthroscopic irrigation
and drainage was performed. Intraoperative fluid was sent
for gram stain, culture and sensitivity, which later revealed
the presence of Methicillin susceptible staphylococcus aureus,
vancomycin-sensitive Enterococcus spp.a n dSerratia
marcescens.
The patient had no known allergies. After reviewing
antimicrobial susceptibility, he was started on vancomycin
1500 mgs intravenously (IV) every 12 hours (to treat both
Staphylococcus aureus and Enterococcus spp) and ciproflox-
acin 750 mgs by oral induction every 12 hours. The
patient’s vancomycin peak level was at 36.2 mcg/ml, and
the trough level was at 14.7 mcg/ml after the third dose.
The patient’s shoulder pain and swelling improved after
antibiotic treatment. He was discharged and allowed to go
home on IV vancomycin and oral ciprofloxacin. His
platelet count on the day he was started on vancomycin
therapy was 253 × 10
3/mm
3 (the normal range is 150 to
400 × 10
3/mm
3). His complete blood count, vancomycin
peak and trough levels were monitored in the infectious
disease clinic. The platelet count was 231 × 10
3/mm
3 in
the first week and 272 × 10
3/mm
3 in the second week. The
platelet count was 6 × 10
3/mm
3 in the third week after
treatment.
The patient was admitted for further work-up of throm-
bocytopenia. In addition to vancomycin and ciproflox-
acin, he received heparin flushes (50 units daily) for three
weeks to maintain potency of the peripherally inserted
central catheter (PICC). In the emergency department, his
vital signs were reported as 37.4 degrees Celsius tempera-
ture, pulse of 88 per minute, respiratory rate of 18 per
minute and blood pressure of 130/80 mmHg. Further
examination revealed the presence of extensive petechial
hemorrhages on both of his lower extremities. Peripheral
pulses were present and equal in all extremities. A repeat
platelet count in the emergency department yielded a
result of 9 × 10
3/mm
3.
On the first day after admission, administration of aspirin,
vancomycinandheparinflushesofthePICConthepatient
were discontinued. As part of his thrombocytopenia work-
up, blood cultures, a disseminated intravascular coagula-
tion panel and heparin-induced antiplatelet antibodies
were obtained. Given the patient’s presentation, vancomy-
cin-induced anti-platelet antibodies were also ordered -
this was done at the Blood Center of the Wisconsin Platelet
and Neutrophil Immunology Laboratory, using immuno-
fluorescence flow cytometry. These results were reviewed
threedaysafterthebloodspecimenwasdrawn.Duringthis
time, the patient received one unit of platelet transfusion,
which raised his platelet count from 9 × 10
3/mm
3 to 28 ×
10
3/mm
3. On the second day, the patient was given
another unit of platelet transfusion, which further elevated
his platelet count to 60 × 10
3/mm
3. By the third day, his
platelet count had increased to 271 × 10
3/mm
3. He was
discharged home on an initial dose of 100 mg intravenous
tigecycline, followed by 50 mg IV every 12 hours. The
patientcontinuedwithafollow-upattheinfectiousdisease
clinic and his platelet count was already at 344 × 10
3/mm
3
after one week and 338 × 10
3 /mm
3 after two weeks.
The differential diagnoses considered were: 1) dissemi-
nated intravascular coagulopathy; 2) heparin-induced
thrombocytopenia (HIT); and 3) vancomycin-induced
thrombocytopenia (VIT). Disseminated intravascular coa-
gulopathy was ruled out because his prothombin time,
fibrinogen level, D-dimer level and peripheral smear were
all normal. Blood cultures also showed no growth. HIT
was excluded by the absence of heparin-induced anti-
platelet antibodies. A vancomycin-induced anti-platelet
antibody test revealed IgG-positive antibodies detected in
the presence of vancomycin. IgM antibodies were negative.
Page 2 of 4
(page number not for citation purposes)
Journal of Medical Case Reports 2009, 3:7290 http://jmedicalcasereports.com/jmedicalcasereports/article/view/7290Discussion
In general, drugs can cause thrombocytopenia by direct
toxic effect, hapten formation and innocent bystander
immune response [1,15] (Figure 1).
Direct toxic effect
Examples of this response include bone marrow destruc-
tion by myelotoxicity of chemotherapeutic agents [1].
Innocent bystander
In this category, a drug combines with a specific antibody
and is adsorbed into the platelet membrane [1]. An
example of this type is heparin-induced thrombocytope-
nia [1]. In contrast with hapten mediated thrombocyto-
penia (i.e., VIT), the degree of thrombocytopenia in HIT is
moderate, as the nadir-platelet count is 60,000/mm
3 [15]
among 85% to 90% of patients studied,
Hapten formation
In this type of response, (anti-platelet) antibody binds to
drug (vancomycin) or to the drug metabolite-glycoprotein
(glycoproteinIIb-IIIa) complex, [1,15] platelets bear
thousands of copies of glycoprotein IIb/IIIa [15]. These
antibody-coated platelets are cleared from circulation by
macrophages of the mononuclear-phagocytic system,
which recognize the “Fc tail” of drug-dependent anti-
bodies [15]. In about 85% to 90% of patients studied, the
nadir-platelet count is less than 20,000/mm
3 [15]. This
increases the risk of bleeding and hemorrhage [15].
Examples include immune thrombocytopenia, following
the use of vancomycin or quinine [15].
Features of VIT
Prominent features of VIT have been described in recent
studies. [5,15] Patients are usually exposed to vancomycin
for at least six days. Platelet counts drop by a mean of
93% from pre-treatment value. Nadir counts averaging
13,600/mm
3 are reached about eight days after vancomy-
cin treatment (the range is one to 27 days). Platelet counts
return to pre-treatment values after discontinuation of the
drug. One-third of patients have extensive ecchymoses and
hemorrhage (wet purpura). Detection of vancomycin-
induced IgM antibodies in one of 451 normal subjects
raises the possibility that in rare cases, naturally occurring
Figure 1. Mechanism of drug induced thrombocytopenia.
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single dose of vancomycin. However, vancomycin-
induced IgG antibodies were not detected in any of 451
normal subjects studied.
Other features of VIT include the failure of platelet
transfusion to elevate platelet levels in most patients [5]
(77% to 79% in that study). Vancomycin-induced anti-
bodies can persist for months following exposure to
vancomycin. Thrombocytopenia in patients with renal
failure can persist long after vancomycin medication is
discontinued, presumably because of delayed clearance.
Conclusions
The diagnosis of drug-induced thrombocytopenia is often
overlooked. However, it is a potentially life-threatening
condition, and testing with drug-dependent antibodies,
such as vancomycin-induced platelet-reactive antibodies,
can be helpful in identifying the cause of thrombocytope-
nia in patients receiving vancomycin [5].
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